BioXcel Therapeutics Inc BTAI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:06 PM EDT
18.37quote price arrow down-1.05 (-5.41%)
Volume
477,972
52 week range
8.80 - 34.12
Loading...
  • Open19.33
  • Day High19.54
  • Day Low17.66
  • Prev Close19.42
  • 52 Week High34.12
  • 52 Week High Date02/09/23
  • 52 Week Low8.80
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap514.787M
  • Shares Out28.02M
  • 10 Day Average Volume0.88M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • YTD % Change-16.15

KEY STATS

  • Open19.33
  • Day High19.54
  • Day Low17.66
  • Prev Close19.42
  • 52 Week High34.12
  • 52 Week High Date02/09/23
  • 52 Week Low8.80
  • 52 Week Low Date06/14/22
  • Market Cap514.787M
  • Shares Out28.02M
  • 10 Day Average Volume0.88M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • YTD % Change-16.15

RATIOS/PROFITABILITY

  • EPS (TTM)-5.92
  • P/E (TTM)-3.11
  • Fwd P/E (NTM)-2.98
  • EBITDA (TTM)-159.325M
  • ROE (TTM)-111.08%
  • Revenue (TTM)375,000.00
  • Gross Margin (TTM)94.67%
  • Net Margin (TTM)-44,201.33%
  • Debt To Equity (MRQ)121.20%

EVENTS

  • Earnings Date05/08/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On BioXcel Therapeutics Inc

 

Profile

MORE
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BXCL501 is also being developed for the acute...
Peter Mueller Ph.D.
Independent Chairman of the Board
Vimal Mehta Ph.D.
President, Chief Executive Officer, Director
Richard Steinhart
Chief Financial Officer, Senior Vice President
Address
555 Long Wharf Dr
New Haven, CT
06511-6107
United States

Top Peers

SYMBOLLASTCHG%CHG
PRVB
Provention Bio Inc
23.87-0.12-0.50%
SANA
Sana Biotechnology Inc
3.50UNCHUNCH
IBRX
Immunitybio Inc
1.38-0.03-2.48%
ETNB
89Bio Inc
11.87-0.57-4.58%
JANX
Janux Therapeutics Inc
11.66-0.27-2.26%